A INTRODUCTION AND SCOPE OF REASONS
1 Before the Court are two applications pursuant to s 33V of the Federal Court of Australia Act 1976 (Cth) (FCA Act) for approval of a proposed settlement in the following open class representative proceedings: Gill & Ors v Ethicon Sàrl & Ors (NSD 1590 of 2012) (Gill Proceeding); and Talbot v Ethicon Sàrl & Ors (NSD 310 of 2021) (Talbot Proceeding).
2 The parties have agreed upon a sum of $300,000,000 to settle all group member claims and liabilities across both proceedings. Notwithstanding some hesitation, I have decided to approve the settlement sum, but I have not agreed to make the orders initially proposed by the applicants.
3 My usual practice with s 33V applications is to deliver judgment ex tempore or as promptly as possible, so as to give certainty to group members. I decided not to take my usual course in the circumstances of this case for four reasons.
4 First, the overall settlement sum is not, for reasons I will explain, sufficiently generous as to be self-evidently fair, given the failure of Ethicon Sàrl, Ethicon, Inc., and Johnson & Johnson Medical Pty Ltd (together, Ethicon) in their opposition to the claims advanced both at the initial trial and on appeal in the Gill Proceeding. One can readily understand a group member rationally forming the impression that this is litigation where big-pocketed respondents have taken every point (including points eventually shown to be contrary to the true position and wholly devoid of merit) and dragged out the dispute interminably, only to be rewarded at the eleventh hour by a proposed settlement which reduces Ethicon's likely exposure - with the group members then having to discount the amount to which they are likely entitled and pick up a substantial part of the tab for costs. But, as I will explain, this view needs to be somewhat tempered upon close analysis.
5 Secondly, the settlement approval application came before the Court contemporaneously with a s 33V application in another class action in my docket, namely Debra Fowkes v Boston Scientific Corporation & Anor (NSD 244 of 2021) (Fowkes Proceeding). The Fowkes Proceeding is a class action brought against the manufacturers of pelvic "mesh" devices designed to alleviate pelvic organ prolapse (POP) and stress urinary incontinence (SUI). While there are important differences between the proceedings, many of the factual and legal issues overlap. In particular, the solicitors for the applicants and the Court received a large number of objections from group members in both proceedings. This partial overlap made it appropriate to deliver judgment in both matters on the same date: see Fowkes v Boston Scientific Corporation [2023] FCA 230.
6 The third reason, somewhat connected to the first, relates to complications and well-founded concerns that arose as to the distribution of money paid under the settlement.
7 The legal representatives for the applicants in both proceedings, Shine Lawyers (Shine) obtained a very substantial amount pursuant to adverse costs orders. But they also seek payment out of the proposed settlement sum on account of unpaid past cost and disbursements, including, novelly, an amount referable to interest payable on a disbursement funding facility. Given the likely scrutiny as to costs on the settlement application, I granted leave for Shine to be separately represented.
8 As it stands, notwithstanding Shine has already been paid, pursuant to existing costs orders, a sum of $41,313,575.73 (and, as I understand it, a further unspecified costs awarded upon dismissal of the special leave application), it now seeks further amounts for past costs and disbursements of $38,131,096.53 (comprising $37,459,569.29 for unrecovered fees and disbursements in the Gill Proceeding and $671,527.24 for unrecovered fees and disbursements in the Talbot Proceeding). Moreover, Shine seeks an amount of $26,030,878 to meet the interest accrued on the disbursement funding facility.
9 Needless to say, these sums are immense. I am no stranger to the reality that big litigation costs big money. But central to the Court's duty to protect the interests of class members is judicial oversight of legal costs and disbursements. I must be satisfied that the further amount of costs proposed to be deducted from the settlement sum is a just deduction. If the costs-inclusive settlement is approved, every cent paid to the solicitors is a cent not paid to group members.
10 But past costs are not the only issue. The present proposal for settlement names two of Shine's practice leaders as scheme administrators. This is common practice. This is despite me explaining elsewhere that the assumption that solicitors for applicants in proceedings brought under Pt IVA of the FCA Act should become scheme administrators by default is a notion which needs to be exploded: Lifeplan Australia Friendly Society Limited v S&P Global Inc (Formerly McGraw- Hill Financial, Inc) (A Company Incorporated in New York) [2018] FCA 379 (at [52]-[54]).
11 The concerns I ventilated in Lifeplan were picked up in Recommendation 9 of the Australian Law Reform Commission's (ALRC) report Integrity, Fairness and Efficiency - An Inquiry into Class Action Proceedings and Third-Party Litigation Funders (Report 134, December 2018) (at [5.35]-[5.39]) (ALRC Report). The ALRC recommended that Pt 15 of the Class Actions Practice Note (GPN-CA) include a clause that the Court may tender settlement administration, and include processes that the Court may adopt when tendering settlement administration.
12 Here, when settlement subject to documentation and Court approval was struck on 9 September 2022, Shine made an Australian Securities Exchange (ASX) announcement pursuant to ASX Listing Rule 3.1 (which provides that once an entity is or becomes aware of information that a reasonable person would expect to have a material effect on the price or value of the entity's securities, the entity must immediately tell the ASX that information). That announcement provided that "[s]ubject to the timing of the Court's approval, cash is expected to be positively impacted in FY23". Regrettably, as I explain below, this anxiety to inform the market as to the expectation of the material augmentation of revenue for Shine was not matched by an anxiety in ensuring the settlement documentation was completed quickly, thus triggering an obligation for the $300,000,000 to be paid and causing interest to accrue for the benefit of group members.
13 Shine estimated that the "[t]otal costs of administration of the settlement scheme" would be up to $36,860,750. On any view, being appointed administrator of a scheme of this scope presents a significant commercial opportunity. It seems passing strange that it should continue to be assumed that the Court would just allow such a commercial opportunity to be taken by the solicitors acting for the applicants without exploring whether there were other cheaper and better ways to distribute the settlement sum justly among group members.
14 Even though this exploration might be contrary to the interests of Shine, one would have thought at least exploring such options would have been consistent with the duties of the representative applicants to group members. But it was only over their opposition that I made orders on 21 December 2022 providing for a tender process to take place to enable consideration of alternative settlement schemes and alternative settlement administrators.
15 As I explain in separate reasons delivered at the same time as this judgment (Gill v Ethicon Sàrl (No 11) [2023] FCA 229), I have already seen enough to confirm my initial (wholly unremarkable view) that competition is likely to produce a better outcome for group members when it comes to price and assist in fastening upon the optimal way of distributing the funds. In any event, these issues as to past and future costs and disbursements are matters worthy of further exploration and close consideration.
16 As a result, on the final day of hearing, I bifurcated the settlement approval process, such that in the event that settlement is approved, I will determine the distribution of funds paid under the settlement at a later date. This approach is consistent with the text of s 33V. Sections 33V(1) and 33V(2) confer two distinct, but related, powers: first, to approve the settlement; and, secondly, if the approval is given, to approve the distribution of payments made under the settlement: Davis v Quintis Ltd (Subject to Deed of Company Arrangement) [2022] FCA 806 (at [3] per Lee J); Botsman v Bolitho [2018] VSCA 278; (2018) 57 VR 68 (at 111 [198]-[203] per Tate, Whelan and Niall JJA); Davaria Pty Ltd v 7-Eleven Stores Pty Ltd [2020] FCAFC 183; (2020) 281 FCR 501 (at 506-507 [23] per Lee J, with whom Middleton and Moshinsky JJ agreed).
17 Fourthly, and importantly, another reason for reserving was because the Court heard numerous accounts of women who have suffered and continue to suffer an array of physical, psychological and psychosocial difficulties. Certainty and closure are especially important in a case of this kind, which (remarkably) has now been on foot for over a decade, and in respect of which common liability findings have already been made (and are now beyond challenge following an unsuccessful Full Court appeal and special leave application). But it was appropriate to take some time to reflect on these accounts and satisfy myself that what is proposed is fair for those women who are group members and have suffered greatly.
18 In dealing with the settlement, these reasons are divided as follows:
B Litigation History;
C The Proposed Settlement;
D Notification and Reactions to the Proposed Settlement;
E Relevant Principles;
F Fairness and Reasonableness of the Proposed Settlement; and
G Conclusion and Orders.